|Mitochondrial Antibodies||TGF Dysregulations|
Mitochondrial Antibodies occur in about 95% of people who have primary biliary cirrhosis (PBC), but only 3% of people who have PBC have systemic scleroderma. (Also see What is Scleroderma? and Types of Scleroderma)
United Mitochondrial Disease Foundation. Mitochondrial diseases result from failures of the mitochondria, specialized compartments present in every cell of the body except red blood cells. Mitochondria are responsible for creating more than 90% of the energy needed by the body to sustain life and support growth. When they fail, less and less energy is generated within the cell. United Mitochondrial Disease Foundation.
Human enteric neuropathies: morphology and molecular pathology. The aim of this study is to review current understanding of the molecular and morphological pathology of the enteric neuropathies affecting motor function of the human gastrointestinal tract. PubMed, Neurogastroenterol Motil. 2004 Oct;16(5):515-31. (Also see GI Involvement)
Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. Primary biliary cirrhosis (PBC) is a chronic liver disease characterized by damage to, and destruction of, the biliary epithelial cells lining small intra-hepatic bile ducts.1 PBC exhibits a number of autoimmune features, including the almost universal presence of auto-antibodies reactive with highly conserved mitochondrial antigens (anti-mitochondrial antibodies, AMA). Q J Med 2004; 97: 397-406. (Also see Liver Involvement)
Study Shows Treatment with Fresolimumab Able to Reduce Skin Scarring in Systemic Scleroderma patients. Fresolimumab, sponsored by Genzyme, a drug agent that targets a chemical mediator in the body called TGF-beta, is able to block scarring which could mean a major treatment advance for scarring-mediated organ dysfunction. Scleroderma News, 06/23/2015. (Also see Skin Fibrosis and Scleroderma Clinical Trials)
Skin involvement in scleroderma--where histological and clinical scores meet. The histological extent of skin fibrosis correlates closely with the mRSS. Both parameters appeared to regress after HSCT (haematopoietic stem cell transplantation). The extent of TGF-beta signalling activation in SSc skin fibroblasts appears to parallel the severity of disease. PubMed, Rheumatology (Oxford). 2007 Jan 25. (Also see Skin Fibrosis)
Urticarial vasculitis appearing in the progression of systemic sclerosis (SSc). We demonstrate that, in the present case, mast cells might be involved in both courses of urticarial vasculitis and SSc as a common factor. PubMed, J Dermatol. 2006 Nov;33(11):792-7. (Also see Vasculitis, Skin Fibrosis, and Limited Scleroderma)
A clue for telangiectasias in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Patients with elevated sEndoglin levels had telangiectasia more frequently than those with normal sEndoglin levels. PubMed, Dermatology. 2006;213(2):88-92. (Also see Telangiectasia, Pulmonary Hypertension, and Limited Scleroderma)
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.